Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12
Permitted Use Tenant shall use the Premises solely for the Permitted Use set forth in Section 7 of the Summary and Tenant shall not use or permit the Premises or the Project to be used for any other purpose or purposes whatsoever without the prior written consent of Landlord, which may be withheld in Landlord’s sole discretion.
